Douglas S. Goodin

17.3k citations

150 papers · 10.3k indexed · 3 hit papers · h-index 56

Pathology and Forensic Medicine top 0.05%
Neurology top 0.2%
Cognitive Neuroscience top 1%
Rheumatology top 0.5%
Molecular Biology top 10%

Co-authors: Michael J. Aminoff Kenneth C. Squires Arnold Starr A. Starr Bruce Cree Fred Lublin Daniel Pelletier Emmanuelle Waubant
Topics: Multiple Sclerosis Research Studies (77 papers)EEG and Brain-Computer Interfaces (25 papers)Systemic Lupus Erythematosus Research (19 papers)
Cited by: Pathology and Forensic Medicine Neurology Cognitive Neuroscience
Journals: Nature PLoS ONE Brain
Partner nations: United States Germany Canada

In The Last Decade

Douglas S. Goodin

146 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

2014 664 citations Peter A. Calabresi, Douglas S. Goodin et al. The Lancet Neurology profile →
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]

2002 603 citations Douglas S. Goodin, Fred Lublin et al. Neurology profile →
Age-related variations in evoked potentials to auditory stimuli in normal human subjects

1978 520 citations Douglas S. Goodin, Arnold Starr et al. Electroencephalography and Clinical Neurophysiology profile →

Peers

Countries citing papers authored by Douglas S. Goodin

Since Specialization

Citations

This map shows the geographic impact of Douglas S. Goodin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas S. Goodin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas S. Goodin more than expected).

Fields of papers citing papers by Douglas S. Goodin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas S. Goodin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas S. Goodin. The network helps show where Douglas S. Goodin may publish in the future.

Co-authorship network of co-authors of Douglas S. Goodin

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas S. Goodin. A scholar is included among the top collaborators of Douglas S. Goodin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas S. Goodin. Douglas S. Goodin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pathogenesis of multiple sclerosis: genetic, environmental and random mechanisms 2024 ·Journal of Neurology Neurosurgery & Psychiatry ·Douglas S. Goodin	5
2	The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities 2016 ·BMC Neurology ·Douglas S. Goodin	12
3	The epidemiology of multiple sclerosis 2016 ·Handbook of clinical neurology ·Douglas S. Goodin	101
4	Patient centered decision making: Use of conjoint analysis to determine risk–benefit trade-offs for preference sensitive treatment choices 2014 ·Journal of the Neurological Sciences ·Leslie Wilson,(unknown),(unknown),(unknown),Lixian Zhong,(unknown),Elizabeth Crabtree,Douglas S. Goodin,Emmanuelle Waubant,Charles E. McCulloch	64
5	The epidemiology of multiple sclerosis 2014 ·Handbook of clinical neurology ·Douglas S. Goodin	133
6	Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States 2014 ·PLoS ONE ·Douglas S. Goodin,Michael J. Corwin,David W. Kaufman,Howard L. Golub,(unknown),Mark Rametta,Volker Knappertz,Gary Cutter,Dirk Pleimes	30
7	Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102) 2013 ·Neurology ·Douglas S. Goodin,Douglas Jeffery,Ludwig Kappos,Fred Lublin,Ernst‐Wilhelm Radue,Kottil Rammohan,Anthony T. Reder,Timothy Vollmer,Mark Agius,Tracy Stites,Bingbing Li,Linda Cappiello,Philipp von Rosenstiel,Peter A. Calabresi	4
8	Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis 2013 ·JAMA Neurology ·Hans Hartung,Lawrence Steinman,Douglas S. Goodin,Giancarlo Comi,Stuart D. Cook,Massimo Filippi,Paul O’Connor,Douglas Jeffery,Ludwig Kappos,Robert C. Axtell,Volker Knappertz,Timon Bogumil,Susanne Schwenke,Ed Croze,Rupert Sandbrink,Christopher Pohl	28
9	Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study 2012 ·BMJ Open ·Douglas S. Goodin,George C. Ebers,Gary Cutter,Stuart D. Cook,Timothy J. O’Donnell,Anthony T. Reder,Marcelo Kremenchutzky,Joël Oger,Mark Rametta,K. Beckmann,Volker Knappertz	38
10	The Genetic and Environmental Bases of Complex Human-Disease: Extending the Utility of Twin-Studies 2012 ·PLoS ONE ·Douglas S. Goodin	13
11	250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study 2009 ·The Lancet Neurology ·Paul O’Connor,Massimo Filippi,Barry G.W. Arnason,Gıancarlo Comı,Stuart D. Cook,Douglas S. Goodin,Hans-Peter Hartung,Douglas Jeffery,Ludwig Kappos,Francis Boateng,В. Л. Филиппов,(unknown),Volker Knappertz,Christian Kraus,Rupert Sandbrink,Christoph Pohl,Timon Bogumil	295
12	Incidental MRI anomalies suggestive of multiple sclerosis 2008 ·Neurology ·Darin T. Okuda,Ellen M. Mowry,A. Beheshtian,Emmanuelle Waubant,Sergio E. Baranzini,Douglas S. Goodin,S L Hauser,Daniel Pelletier	392
13	Disease-modifying therapy in MS: a critical review of the literature 2004 ·Journal of Neurology ·Douglas S. Goodin	10
14	Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans 2004 ·The American Journal of Human Genetics ·Jorge R. Oksenberg,Lisa F. Barcellos,Bruce Cree,Sergio E. Baranzini,Teodorica L. Bugawan,Omar Khan,Robin Lincoln,(unknown),Emmanuel Mignot,Ling Lin,Douglas S. Goodin,(unknown),Silke Schmidt,Glenys Thomson,David Reich,Margaret A. Pericak‐Vance,Jonathan L. Haines,Stephen L. Hauser	236
15	Disease-modifying therapies for multiple sclerosis 2003 ·Current Treatment Options in Neurology ·John R. Corboy,Douglas S. Goodin,Elliot M. Frohman	24
16	Late electromyographic activity following stretch in human forearm muscles: physiological role 1994 ·Brain Research ·(unknown),Douglas S. Goodin,Michael J. Aminoff,(unknown)	5
17	IFCN recommended standards for brain-stem auditory evoked potentials. Report of an IFCN committee 1994 ·Electroencephalography and Clinical Neurophysiology ·Marc R. Nuwer,Michael J. Aminoff,Douglas S. Goodin,Shigeaki Matsuoka,François Mauguı̀ere,Arnold Starr,Jean-François Vibert	45
18	In vivo detection of myelin phospholipids in multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging 1994 ·Annals of Neurology ·Cynthia Husted,Gerald B. Matson,Dorothy A. Adams,Douglas S. Goodin,Michael W. Weiner	20
19	EVIDENCE THAT THE LONG-LATENCY STRETCH RESPONSES OF THE HUMAN WRIST EXTENSOR MUSCLE INVOLVE A TRANSCEREBRAL PATHWAY 1990 ·Brain ·Douglas S. Goodin,Michael J. Aminoff,Patricia Shih	50
20	Recovery of peripheral and central responses to median nerve stimulation 1988 ·Electroencephalography and Clinical Neurophysiology ·Ricardo Reisin,Douglas S. Goodin,Michael J. Aminoff,Mary Mantle	13

About Douglas S. Goodin

Douglas S. Goodin is a scholar working on Pathology and Forensic Medicine, Rheumatology and Cognitive Neuroscience, having authored 150 papers that have together received 10.3k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (77 papers), EEG and Brain-Computer Interfaces (25 papers) and Systemic Lupus Erythematosus Research (19 papers). The work is most often cited by research in Pathology and Forensic Medicine (5.3k citations), Neurology (2.7k citations) and Cognitive Neuroscience (2.0k citations). Douglas S. Goodin has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Michael J. Aminoff, Kenneth C. Squires, Arnold Starr, A. Starr, Bruce Cree, Fred Lublin, Daniel Pelletier, Emmanuelle Waubant, Anthony T. Reder and Volker Knappertz. Their work appears in journals such as Nature, PLoS ONE and Brain.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact